Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?
Identificadores
Identificadores
Data de publicación
2014Título da revista
AMERICAN JOURNAL OF HEMATOLOGY
Tipo de contido
Artigo